Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2021 from OUS - Department of Cancer Immunology

9 publications found

Jiang X, Bergquist A, Löscher BS, Venkatesh G, Mold JE, Holm K, Laerdahl JK, Skånland SS, Maleki KT, Cornillet M, Taskén K, Franke A, Karlsen TH, Björkström NK, Melum E (2021)
A heterozygous germline CD100 mutation in a family with primary sclerosing cholangitis
Sci Transl Med, 13 (582)
DOI 10.1126/scitranslmed.abb0036, PubMed 33627483

Lone AM, Taskén K (2021)
Phosphoproteomics-Based Characterization of Prostaglandin E2 Signaling in T Cells
Mol Pharmacol, 99 (5), 370-382
DOI 10.1124/molpharm.120.000170, PubMed 33674363

Maura F, Boyle EM, Rustad EH, Ashby C, Kaminetzky D, Bruno B, Braunstein M, Bauer M, Blaney P, Wang Y, Ghamlouch H, Williams L, Stoeckle J, Davies FE, Walker BA, Maclachlan K, Diamond B, Landgren O, Morgan GJ (2021)
Chromothripsis as a pathogenic driver of multiple myeloma
Semin Cell Dev Biol (in press)
DOI 10.1016/j.semcdb.2021.04.014, PubMed 33958284

Mester S, Evers M, Meyer S, Nilsen J, Greiff V, Sandlie I, Leusen J, Andersen JT (2021)
Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn in vitro and in vivo
mAbs, 13 (1), 1893888

Rustad EH, Nadeu F, Angelopoulos N, Ziccheddu B, Bolli N, Puente XS, Campo E, Landgren O, Maura F (2021)
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
Commun Biol, 4 (1), 424
DOI 10.1038/s42003-021-01938-0, PubMed 33782531

Sioud M (2021)
RNA Interference: Story and Mechanisms
Methods Mol Biol, 2282, 1-15
DOI 10.1007/978-1-0716-1298-9_1, PubMed 33928566

Sioud M (2021)
Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy
EBioMedicine, 67, 103351 (in press)
DOI 10.1016/j.ebiom.2021.103351, PubMed 33965875

Skånland SS, Mato AR (2021)
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Blood Adv, 5 (1), 334-343
DOI 10.1182/bloodadvances.2020003423, PubMed 33570649

Sullivan LC, Nguyen THO, Harpur CM, Stankovic S, Kanagarajah AR, Koutsakos M, Saunders PM, Cai Z, Gray JA, Widjaja JML, Lin J, Pietra G, Mingari MC, Moretta L, Samir J, Luciani F, Westall GP, Malmberg KJ, Kedzierska K, Brooks AG (2021)
Natural killer cell receptors regulate responses of HLA-E-restricted T cells
Sci Immunol, 6 (58)
DOI 10.1126/sciimmunol.abe9057, PubMed 33893172

 
Page visits: 575511